NEO101 - LEO Pharma

Drug Profile

NEO101 - LEO Pharma

Alternative Names: NEO-101 - LEO Pharma

Latest Information Update: 20 Jun 2016

Price : $50

At a glance

  • Originator Neosil
  • Developer LEO Pharma
  • Class Anti-infectives; Biguanides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acne; Atopic dermatitis; Bacterial infections; Burns; Staphylococcal infections

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top